Home

LINDA BADDOUR

CIK 1181151 · Executive VP & CFO · last filed 2026-06-09

LINDA BADDOUR is an Executive VP & CFO who has filed 46 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for CYRX, was dated Jun 9, 2026. Across all open-market trades the lifetime net is −$44.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions. 21 SEC filings were submitted jointly with PHARMACEUTICAL PRODUCT DEVELOPMENT INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.38M

Companies

5

Total Filings

46

Lifetime Open-Market Net

-$44.75M

Filer Profile

Reported Address
PRA INTERNATIONAL
12120 SUNSET HILLS ROAD, SUITE 600
RESTON, VA 20190
Related Filers
PHARMACEUTICAL PRODUCT DEVELOPMENT INC — 21 joint filings, latest 2008-01-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CYRX Director 68,099 $17.02 $1.16M $0 11 2026-06-09
WAT Director 2,899 $421.63 $1.22M -$1.09M 13 2026-02-27
PRA Health Sciences, Inc. (PRAH) Delisted Executive VP & CFO 67,000 $165.21 $11.07M -$37.87M 11 2018-01-18
PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Former Chief Financial Officer 22,057 — — -$5.79M 8 2008-01-25
PRA International (PRAI) Delisted EVP and CFO — — — $0 1 2007-06-06

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-09 CYRX Grant (A) +10,350 $0 EDGAR
2026-02-27 WAT Grant (A) +23 $0 EDGAR
2026-01-05 WAT Grant (A) +307 $0 EDGAR
2025-06-10 CYRX Grant (A) +23,214 $0 EDGAR
2025-01-06 WAT Grant (A) +319 $0 EDGAR
2024-05-21 CYRX Grant (A) +12,845 $0 EDGAR
2024-03-19 CYRX Exer (M) +1,111 $0 EDGAR
2024-03-14 WAT Sell (S) −500 -$177.8K EDGAR
2024-03-13 WAT Notice (144) −500 -$177.8K EDGAR
2024-01-03 WAT Grant (A) +334 $0 EDGAR
Showing 1–10 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.